. Author manuscript; available in PMC: 2014 Mar 1.

Published in final edited form as: Clin Cancer Res. 2013 Jan 22;19(5):1281–1289. doi: 10.1158/1078-0432.CCR-12-3029

Table 1.

Amplification by arm of trial and ER/PR/HER2 status

	n	Amplified + borderline amplified n (%)	Amplified (ratio ≥ 2)	Borderline amplified (ratio ≥ 1.5 but < 2)	Normal	Deleted (ratio < 0.8)
All patients	324	52 (16.0%)	21	31	251	21
Arm A	157	24 (15.3%)	6	18	120	13
Arm B	167	28 (16.8%)	15	13	131	8
ER+ or PR+/HER2−	210	26 (12.4%)	6	20	172	12
TNBC	100	23 (23.0%)	13	10	69	8
HER2+	6	3 (50.0%)	2	1	2	1

Ratio= VEGF-A/CEN-6 signal ratio; TNBC=triple negative breast cancer; Arm A=paclitaxel with bevacizumab; Arm B= paclitaxel alone